Dr. Daisuke Nishizawa, Ph.D., is a Research Fellow and Head of the Laboratory of Psychotropic Drug Development at the National Center of Neurology and Psychiatry (NCNP), Japan. He received his academic training in biological anthropology and neuroscience and has devoted his career to investigating the genetic basis of individual differences in drug responses and disease susceptibility.
His research focuses on human genetics, pharmacogenomics, and precision medicine, particularly in pain, addiction, and neuropsychiatric disorders. He has conducted genome-wide association studies (GWAS), candidate gene analyses, methylation studies, and transcriptomic analyses to identify genetic factors associated with opioid sensitivity, postoperative nausea and vomiting, substance use disorders, and chronic pain.
Dr. Nishizawa is particularly recognized for his studies on genetic polymorphisms in OPRM1, KCNJ6, and other genes associated with pain sensitivity and opioid responses, as well as recent findings on opioid-induced nausea and the sedative effects of midazolam. He has authored more than 90 peer-reviewed publications and contributed to several patents related to pharmacogenomic evaluation methods.
He is a member of several professional societies in pharmacology, neuroscience, pain research, and human genetics, and continues to promote personalized medicine for pain management, addiction, and psychiatric disorders.
Dr. Daisuke Nishizawa, Ph.D., is a Research Fellow and Head of the Laboratory of Psychotropic Drug Development at the National Center of Neurology and Psychiatry (NCNP), Japan. He received his academic training in biological anthropology and neuroscience and has devoted his career to investigating the genetic basis of individual differences in drug responses and disease susceptibility.
His research focuses on human genetics, pharmacogenomics, and precision medicine, particularly in pain, addiction, and neuropsychiatric disorders. He has conducted genome-wide association studies (GWAS), candidate gene analyses, methylation studies, and transcriptomic analyses to identify genetic factors associated with opioid sensitivity, postoperative nausea and vomiting, substance use disorders, and chronic pain.
Dr. Nishizawa is particularly recognized for his studies on genetic polymorphisms in OPRM1, KCNJ6, and other genes associated with pain sensitivity and opioid responses, as well as recent findings on opioid-induced nausea and the sedative effects of midazolam. He has authored more than 90 peer-reviewed publications and contributed to several patents related to pharmacogenomic evaluation methods.
He is a member of several professional societies in pharmacology, neuroscience, pain research, and human genetics, and continues to promote personalized medicine for pain management, addiction, and psychiatric disorders.